SynAct Pharma Revenue
Biotechnology Research • 
Lund, Skåne County, Sweden • 11-20 Employees
SynAct Pharma revenue & valuation
| Annual revenue | $1,026,660 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $3,300,000 |
| Total funding | $7,885,700 |
Key Contact at SynAct Pharma
Anna-Karin Robertson
Director Translational Pharmacology
Company overview
| Headquarters | Medicon Village AB, Sheelevägen 2, Lund, SE-223 81, SE |
| Phone number | +4528447567 |
| Website | |
| NAICS | 541714 |
| Keywords | Biotechnology, Inflammation, Rheumatoid Arthritis, Covid-19, Melanocortins, Nephrotic Syndrome |
| Founded | 2013 |
| Employees | 11-20 |
| Socials |
SynAct Pharma Email Formats
SynAct Pharma uses 5 email formats. The most common is {first name}.{last name}@company.com (e.g., john.doe@company.com), used 42.1% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name}@company.com | john.doe@company.com | 42.1% |
{first name}@company.com | john@company.com | 25.3% |
{first name initial}{last name}@company.com | {first name initial}doe@company.com | 14.8% |
{first name}{last name}@company.com | johndoe@company.com | 10.2% |
{last name}@company.com | doe@company.com | 7.6% |
About SynAct Pharma
SynAct Pharma is a biotech company aiming at resolving inflammation by leveraging melanocortin biology. Our lead asset AP1189 is in phase 2 development for the treatment of rheumatoid arthritis. AP1189 is an immunomodulatory small molecule delivered as a once-daily tablet. The mode of action is selective melanocortin receptor type 1 and 3 agonism, making it first-in-class. Activation of these receptors results in reduced secretion of proinflammatory cytokines by neutrophils and in conversion of macrophages towards clearing away cellular debris in hyper-inflamed tissue – two effects that together induce resolution of inflammation. The Phase 2a BEGIN study in patients with rheumatoid arthritis reported very promising efficacy and safety results in November 2021 - next step is to open an IND with FDA to get advice on further development. Due to the known Mode of Action, then AP1189 was also tested in COVID-19 positive patients with respiratory insufficiency. Results were reported in July 2021, demonstrating 4 days earlier respiratory recovery, 3 days earlier hospital discharge and more than 50% reduced risk of progressing to needing mechanical ventilation.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
SynAct Pharma has 4 employees across 3 departments.
Departments
Number of employees
Funding Data
Explore SynAct Pharma's funding history, including investment rounds, total capital raised, and key backers.
SynAct Pharma Tech Stack
Discover the technologies and tools that power SynAct Pharma's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Cookie compliance
Miscellaneous
JavaScript libraries
CDN
JavaScript libraries
Programming languages
Blogs
UI frameworks
Performance
Tag managers
Hungary
Fiji
Netherlands
United States
Poland
Frequently asked questions
4.8
40,000 users
